The biotech & life sciences sector in Switzerland

22 investors from the directory fund this sector in Switzerland. We track 46 rounds, about CHF 581.9 M announced, mostly grant.

What changes in this sector

Clinical trials
A drug trial goes through the ethics committee (BASEC portal) and, for categories B and C, through Swissmedic. Both applications can be filed in parallel, but the trial only starts with both approvals. Swissmedic, clinical trials of medicinal products
Funding path
The most capital-hungry sector: grants and Innosuisse for proof of concept, then life-science funds that finance phase by phase. Each round is tied to a scientific or clinical result.
Intellectual property
For a spin-off, the licence negotiated with the university's technology transfer office is the first document an investor will read.
What investors look at
The strength of the preclinical data, patent protection, the clinical development plan and the scientific team.
Where it happens
Basel, Biopôle in Lausanne, Campus Biotech in Geneva and the Bio-Technopark Schlieren.

Checked on 5 November 2026. An error or a rule change? Write to us.

Who keeps coming back in rounds

Recent rounds

November 2026

October 2026

  • DecodeNAture

    DecodeNAture rapidly identifies DNA in the field for agriculture, biosecurity and biodiversity monitoring.

    Prize · Lausanne · Biotech & life sciences · MassChallenge CH

    CHF 10,000
  • Topadur Pharma

    Topadur Pharma develops locally acting small molecules for wound healing and fibrosis, including TOP-N53, which is in phase 2a.

    Undisclosed round · Biotech & life sciences · DEBRA Research

    Amount not disclosed
  • Biodelphis Therapeutics

    Biodelphis Therapeutics, an EPFL spin-off, couples a small molecule with an antibody to treat osteoporosis without acting on the whole body.

    Loan · Lausanne · Biotech & life sciences · FIT Vaud (Innovaud)

    CHF 100,000
  • Atlas Bio

    Atlas Bio uses AI to simulate clinical trials and drug behaviour, in order to replace part of phase II trials and animal testing.

    Seed · Basel · Biotech & life sciences · Creandum

    USD 10 M
  • Juturna Bio

    Juturna Bio, an EPFL spin-off based at the Campus Biotech, is developing epigenetic therapies to restore the function of ageing brain cells, with Alzheimer's as the first target.

    Grant · Geneva · Biotech & life sciences · FIF Genève

    CHF 50,000
  • Nouscom

    Nouscom is developing NOUS-209, a neoantigen-based immunotherapy designed to prevent cancers in carriers of Lynch syndrome.

    Series C and later · Basel · Biotech & life sciences · M Ventures, Revelation Partners, Angelini Industries and 12 more

    USD 135 M

September 2026

All rounds in biotech & life sciences →

Active investors in the sector

  • BaseLaunch Accelerator · Seed · Up to CHF 500K
  • ACE Ventures VC · Seed and stage not specified across recorded rounds · Ticket sizes not disclosed; recorded rounds of USD 3 M to USD 5.4 M
  • Angelini Ventures CVC · Series B to Series C across recorded rounds · Ticket sizes not disclosed; recorded rounds of CHF 26 M to USD 135 M
  • Backbone Ventures VC · Pre-seed and stage not specified across recorded rounds · Ticket sizes not disclosed; recorded rounds of CHF 2.4 M to USD 3 M
  • Biopôle SA Grant · Non-dilutive funding for start-ups on the Biopôle campus · Up to CHF 90 000 per start-up, plus a CHF 250 000 Pre-Clinical Top-Up
  • CDP Venture Capital VC · Series A to Series C across recorded rounds · Ticket sizes not disclosed; recorded rounds of EUR 3 M to USD 135 M
  • Creandum VC · Seed to Series A across recorded rounds · Ticket sizes not disclosed; recorded rounds of USD 10 M to USD 40 M
  • EQT Life Sciences VC · Series A to Series C across recorded rounds · Ticket sizes not disclosed; recorded rounds of USD 50 M to USD 152 M
  • Eurostars Grant · Non-dilutive R&D grants to consortia across recorded rounds · Eurostars funding of EUR 1 to 1.3 M per consortium (including EUR 772 000 for Terapet)
  • Forty51 Ventures VC · Seed across recorded rounds · Ticket sizes not disclosed; recorded rounds of USD 3.5 M to USD 5.1 M
  • GoHub Ventures VC · Seed across recorded rounds · Ticket sizes not disclosed
  • Goldman Sachs Alternatives VC · Series B to Series C across recorded rounds · Ticket sizes not disclosed; recorded rounds of USD 100 M to USD 152 M
  • High-Tech Gründerfonds VC · Pre-seed to Series C, mostly seed, across recorded rounds · Ticket sizes not disclosed; recorded rounds of EUR 3 M to USD 100 M
  • Lichtsteiner Foundation Grant · Seed across recorded rounds · Tickets not disclosed; recorded rounds of CHF 1.25 M to USD 5.1 M
  • M Ventures CVC · Series A to Series C across recorded rounds · Tickets not disclosed; recorded rounds of USD 50 M to USD 135 M
  • Neva SGR VC · Series B to Series C across recorded rounds · Tickets not disclosed; recorded rounds of CHF 26 M to USD 135 M
  • Nextech Invest VC · A–B · 5–30M
  • Omega Funds VC · Series B and round not specified across recorded rounds · Tickets not disclosed; recorded rounds of USD 152 M to USD 165 M
  • Perceptive Advisors VC · Series B and debt financing across recorded rounds · Loan of up to USD 70 M (Distalmotion); equity tickets not disclosed
  • Verve Ventures VC · Seed–A · 0.5–10M
  • Y Combinator Accelerator · Accelerator programme, then follow-on through to Series A across recorded rounds · Tickets not disclosed
  • Zürcher Kantonalbank VC · Pre-seed to growth across recorded rounds · Tickets not disclosed; recorded rounds of CHF 1.7 M to USD 25 M